Retained Kenya · PPB

Menactra (Meningococcal (Groups A C Y and W-135)…

Neisseria meningitidis serogroup A C Y and W-135…

What it does

Meningitidis refers to a type of bacteria that can cause meningitis, an infection of the protective membranes covering the brain and spinal cord.

Commonly used for: meningitis (meningococcal infection)

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Hard to find? We help patients in Kenya source rare medicines. We don't sell or dispense medicines - licensed pharmacies do.

Source this medicine

Registration & product details

Registration no.
CTD 053/R1
Registration date
2026 July 14
Expiry date
2031 July 14
Status
Retained
Active ingredient
Neisseria meningitidis serogroup A C Y and W-135…
Strength
-
Pack size
-
Therapeutic class
-
Manufacturer / MAH
Sanofi Pasteur S.a
Applicant / LTR
RESSOURCETHICA KENYA LTD
Country of origin
United States
Manufacturer location
14 Espa. Henri Vallée, 69007 Lyon, France

Source: Pharmacy and Poisons Board · fetched 2026-08-27 13:08:20 · updated 2026-08-28 02:02:55

Disclaimer: This information is sourced from Pharmacy and Poisons Board (Kenya). Always consult a qualified healthcare professional before using any medication.

About meningitidis

Meningitidis refers to a type of bacteria that can cause meningitis, an infection of the protective membranes covering the brain and spinal cord.

What it treats

  • meningitis (meningococcal infection)

How it works

Meningitidis bacteria invade the body and can cause inflammation of the protective layers around the brain and spinal cord, leading to serious health issues.

Who it's for

This condition can affect anyone, but it is particularly dangerous for young children, teenagers, and individuals with weakened immune systems.

Cautions

  • • Seek immediate medical attention if symptoms such as severe headache, stiff neck, or fever occur.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

About neisseria

Neisseria is a type of bacteria that can cause various infections, including those affecting the reproductive system and the throat.

What it treats

  • gonorrhea (a sexually transmitted infection)
  • meningitis (an infection of the protective membranes covering the brain and spinal cord)

How it works

Neisseria bacteria can invade the body and multiply, leading to infection.

Who it's for

People who may be at risk of infections caused by Neisseria, particularly sexually active individuals.

Cautions

  • • Always practice safe sex to reduce the risk of sexually transmitted infections.
  • • Seek medical attention if you experience unusual symptoms such as pain during urination or fever.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: meningitidis

Meningitidis refers to the infection of the protective membranes covering the brain and spinal cord, known as the meninges. It can be caused by various pathogens, including bacteria, viruses, fungi, and parasites. Bacterial meningitis is a serious condition that requires immediate medical attention and is often treated with antibiotics. Common bacterial pathogens include Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type b. Preventive measures, such as vaccination, are also available for certain types of bacterial meningitis.

Indications

  • Bacterial meningitis
  • Viral meningitis
  • Preventive vaccination against meningococcal disease
  • Post-exposure prophylaxis in cases of meningococcal infection

Dosage

Children: Refer to the BNF for Children for dosing recommendations, which will vary based on the specific antibiotic used and the age and weight of the child.

Adults: Refer to local guidelines and the BNF for specific antibiotic dosing regimens according to the pathogen identified and clinical presentation.

Mechanism of action

In cases of bacterial meningitis, antibiotics such as penicillins or cephalosporins work by inhibiting cell wall synthesis, leading to bacterial cell lysis and death. In the context of meningococcal meningitis caused by Neisseria meningitidis, meningococcal vaccines stimulate the immune response against the bacteria, allowing the body to mount an effective defense against future infections.

Pharmacodynamics

The pharmacodynamics of antibiotics used in the treatment of meningitis involve their ability to penetrate the blood-brain barrier, which is crucial for effective treatment of central nervous system infections. The efficacy of these agents is often determined by their ability to achieve adequate concentrations in the cerebrospinal fluid (CSF). Vaccines elicit the production of specific antibodies, providing immunity against the pathogens causing meningitis.

Pharmacokinetics

Pharmacokinetics of antibiotics vary depending on their class. For example, penicillins have good distribution in the CSF, especially when inflammation of the meninges is present. The half-life, metabolism, and excretion routes also vary. Vaccines generally stimulate a long-lasting immune response but do not have a conventional pharmacokinetic profile as they do not act like drugs in the traditional sense.

Pregnancy

Meningococcal vaccines are generally considered safe during pregnancy. However, consult healthcare providers for specific cases.

Breast-feeding

The meningococcal vaccine is safe during breastfeeding. Consult healthcare providers for individual assessment.

Storage

Store at 2 to 8 degrees Celsius. Do not freeze. Protect from light.

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Clinical monograph: neisseria

Neisseria is a genus of bacteria that includes pathogenic species, such as Neisseria meningitidis, which causes meningococcal disease, and Neisseria gonorrhoeae, which is responsible for gonorrhea. These bacteria are Gram-negative diplococci, characterized by their round shape and tendency to appear in pairs. They are known to inhabit mucosal surfaces and can cause significant systemic diseases if they invade the bloodstream or central nervous system.

Indications

  • Meningococcal disease (caused by Neisseria meningitidis)
  • Gonorrhea (caused by Neisseria gonorrhoeae)
  • Pelvic inflammatory disease
  • Septic arthritis

Dosage

Children: Refer to appropriate clinical guidelines for specific dosing of antibiotics used to treat

Adults: Refer to appropriate clinical guidelines for specific dosing of antibiotics used to treat Neisseria infections.

Mechanism of action

Neisseria species adhere to and invade epithelial cells through the action of pili and outer membrane proteins. They evade the immune response by varying their surface antigens and producing factors such as endotoxin and proteases. Neisseria meningitidis can enter the bloodstream and cross the blood-brain barrier, leading to inflammation and potentially severe outcomes such as meningitis or septicemia. Neisseria gonorrhoeae primarily infects the urogenital tract and can cause local inflammation and complications if untreated.

Pharmacodynamics

The pathogenesis of Neisseria involves complex interactions with the host's immune system, including the ability to resist phagocytosis. The bacteria can produce a polysaccharide capsule, particularly in Neisseria meningitidis, which enhances virulence by inhibiting opsonization and phagocytosis. The inflammatory response to these infections can lead to symptoms such as fever, headache, and, in the case of meningitis, neck stiffness.

Pharmacokinetics

Neisseria species do not have a defined pharmacokinetic profile as they are pathogens rather than drugs. However, the pharmacokinetics of antibiotics used to treat infections caused by Neisseria, such as penicillin or ceftriaxone, would be relevant. These antibiotics are typically well-absorbed, distributed throughout the body, and excreted by the kidneys, with adjustments needed for renal impairment.

Pregnancy

There is limited data on the use of Neisseria species during pregnancy. Caution is advised, and benefits should be weighed against potential risks.

Breast-feeding

Caution is advised when administering medications targeting Neisseria species during breastfeeding due to limited data on excretion in human milk.

Storage

Store in a cool, dry place, away from direct sunlight. Specific storage requirements may vary based on the formulation and manufacturer's guidelines.

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Clinical monograph: w135

W135 is a medication whose specific identity and details are not provided in standard drug references. Based on established pharmacology, it may refer to a compound used for various therapeutic purposes, but without specific details, it is difficult to provide a comprehensive overview.

Dosage

Children: For paediatric dosages, it is essential to consult the BNF for Children or other specialized pediatric references, as no specific dosing information is provided.

Adults: For dosage in adults, refer to the specific medication literature or professional guidelines as no precise dosing information is available for W135.

Mechanism of action

The mechanism of action of W135 is not documented in available literature. Generally, medications classified under similar compounds may function through various pathways, including modulation of neurotransmitter release, inhibition of enzyme activity, or altering receptor sensitivity, but specific details for W135 cannot be determined.

Pharmacodynamics

Pharmacodynamics involves the study of the effects of W135 on the body. Without specific pharmacological data, it is challenging to elucidate the precise effects. Typically, similar compounds may exhibit dose-dependent effects, influencing various physiological systems, but this is speculative.

Pharmacokinetics

Pharmacokinetics describes how the body absorbs, distributes, metabolizes, and excretes a drug. For W135, specific pharmacokinetic parameters are not available. However, standard pharmacokinetic profiles would include absorption rates, peak plasma concentrations, half-life, and clearance mechanisms, but these cannot be specified without further information.

Pregnancy

Consult with a healthcare professional before use. Safety during pregnancy has not been established.

Breast-feeding

Consult with a healthcare professional before use. Minimal data is available on excretion in breast milk.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.